Gene therapy injection could ease Parkinson's symptoms

NCT ID NCT07566429

Not yet recruiting Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen May 05, 2026 · Last updated May 06, 2026 · Updated 1 time

Summary

This study tests a single injection of AB-1005 gene therapy directly into the brain for Japanese adults with moderate Parkinson's disease. The goal is to see if it is safe and can improve motor function and reduce daily symptoms. Eight participants will be followed for 18 months after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Juntendo University Hospital - Neurology

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Nagoya Central Hospital - Neurosurgery

    Nagoya, Aichi-ken, 453-0801, Japan

  • Nagoya University Hospital - Neurology

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Hospital Organization Osaka Toneyama Medical Center - Neurology

    Osaka, 560-8552, Japan

  • National Hospital Organization Utano National Hospital - Neurology

    Kyoto, 616-8255, Japan

  • Yokohama City University Medical Center - Neurology

    Yokohama, Kanagawa, 232-0024, Japan

Conditions

Explore the condition pages connected to this study.